beyondspring
present
wainwright
annual
global
investment
conference
september
nasdaq
bysi
new
york
globe
newswire
beyondspring
company
beyondspring
nasdaq
bysi
global
biopharmaceutical
company
focused
developing
innovative
cancer
therapies
transform
lives
patients
unmet
medical
needs
today
announced
management
provide
corporate
overview
wainwright
annual
global
investment
virtual
conference
monday
september
eastern
time
presentation
webcast
live
archived
beyondspring
website
events
presentation
investors
section
company
also
participating
virtual
meetings
conference
beyondspring
headquartered
new
york
beyondspring
global
biopharmaceutical
company
focused
developing
innovative
cancer
therapies
improve
clinical
outcomes
patients
high
unmet
medical
needs
beyondspring
lead
immune
asset
plinabulin
potent
cell
apc
inducer
currently
two
phase
clinical
trials
two
severely
unmet
medical
needs
indications
one
prevention
neutropenia
cin
frequent
cause
chemotherapy
regimen
dose
decrease
delay
downgrade
discontinuation
lead
suboptimal
clinical
outcomes
cell
lung
cancer
nsclc
treatment
egfr
patients
pipeline
drug
plinabulin
various
combination
studies
boost
antibody
effects
addition
plinabulin
beyondspring
extensive
pipeline
includes
three
assets
drug
discovery
platform
dubbed
molecular
glue
uses
protein
degradation
pathway
cautionary
note
regarding
statements
press
release
includes
statements
historical
facts
words
expect
anticipate
plan
believe
design
may
future
estimate
predict
objective
goal
variations
thereof
variations
words
similar
expressions
intended
identify
statements
statements
based
beyondspring
current
knowledge
present
beliefs
expectations
regarding
possible
future
events
subject
risks
uncertainties
assumptions
actual
results
timing
events
could
differ
materially
anticipated
statements
result
several
factors
including
limited
difficulties
raising
anticipated
amount
needed
finance
company
future
operations
terms
acceptable
company
unexpected
results
clinical
trials
delays
denial
regulatory
approval
process
results
meet
expectations
regarding
potential
safety
ultimate
efficacy
clinical
utility
product
candidates
increased
competition
market
risks
described
beyondspring
recent
form
file
securities
exchange
commission
statements
made
herein
speak
date
release
beyondspring
undertakes
obligation
update
publicly
statements
reflect
subsequent
events
circumstances
except
otherwise
required
law
